Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Microdosimetric calculations of boron-drug compound factors for boron neutron capture therapy

Conference · · Transactions of the American Nuclear Society; (United States)
OSTI ID:7033208
 [1]
  1. Idaho National Engineering Lab., Idaho Falls (United States)

The relative biological effect (RBE) is not a useful term to describe {sup 10}B capture events because dose is not a greatly useful term for boron neutron capture therapy (BNCT), and each drug compound exhibits unique pharmacokinetics, resulting in differences in {sup 10}B spatial distributions and tremendous variation in biological effect. These considerations have led to the suggestion that a quantity called the compound factor' (CF) be defined. The CF can replace RBE for BNCT terminology and avoid some misinterpretations caused by quoting RBE values. A study was performed to estimate CFs in normal brain and brain-tumor tissues for borocaptate sodium (Na{sub 2}B{sub 12}H{sub 11}SH (BSH)) and para-boronophenylalanine (p-BPA). A Monte Carlo computer model of the capillaries was used to determine charged-particle energy deposition patterns following {sup 10}B capture events in various regions within and around the endothelial cell. A spherical model of tumor cells was also used to determine energy transport in the tumor. The tumor cells were assumed to be 10 {mu}m in diameter with 5-{mu}m-diam nuclei, and extracellular space occupied 15% of the volume. From these Monte Carlo results, transmission factors were obtained for energy deposition to the nucleus due to {sup 10}B capture events in any region within and external to the cells.

OSTI ID:
7033208
Report Number(s):
CONF-920606--
Journal Information:
Transactions of the American Nuclear Society; (United States), Journal Name: Transactions of the American Nuclear Society; (United States) Vol. 65; ISSN TANSA; ISSN 0003-018X
Country of Publication:
United States
Language:
English